LONDON, August 2, 2016 /PRNewswire/ --
Prima BioMed has progressed to the final stage of dose selection for its Phase IIb trial of IMP321 in breast cancer, and is on track to commence randomization in Q416. IMP321 is a soluble LAG-3 fusion protein that doubled tumor response rates in Phase IIa. Separately, partner Novartis has expanded its Phase I LAG-3 program in solid tumors and GSK plans to move its partnered autoimmune drug into Phase II this year. With the company's development of in-house and partnered LAG-3 programs on track, our valuation increases slightly to $215m ($3.12/ADR).
Our valuation increases to $215m (previously $207m), with a slightly lower valuation of CVac after out-licensing to Sydys more than offset by rolling forward our DCF model to FY17. Our valuation is equal to $3.12 per ADR on an undiluted basis (previously $3.02) or $2.12 per ADR after accounting for dilution from options, warrants and convertible notes (unchanged). We forecast that an extra $6m will be needed to fund operations until end FY18.
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website http://www.edisoninvestmentresearch.com.
About Edison: Edison is an international equity research firm with a team of over 110 analysts, investment and roadshow professionals and works with both large and smaller capitalised companies, blue chip institutional investors, wealth managers, private equity and corporate finance houses to support their capital markets activity. Edison provides services to more than 420 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact:
Dennis Hulme, Edison Investment Research, +61(0)2-9258-1161
Lala Gregorek, Edison Investment Research, +44(0)20-3681-2527, email@example.com
Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:
SOURCE Edison Investment Research